RxDoctor Payments Data

Heidi Foley, MD

Family Medicine · Amherst, MANPI 1801981493

Payments from drug & device makers

$492in general payments, 2019–2025

Across 21 payments — averaging $23.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$85
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$51
  • Amgen$44
  • Novo Nordisk$32
  • Lilly USA, LLC$28
  • Merck$26
  • plus $225 from 11 others

What the payments were for

  • Food & beverage$492100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$492 in reported general payments places this provider in the 75th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$33,787
Medicare patients
127
Services billed
520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$25,961
EliquisApixaban12$16,371
MyrbetriqMirabegron24$15,699
JardianceEmpagliflozin14$15,147
TrulicityDulaglutide13$14,360
JanuviaSitagliptin Phosphate11$9,380
Combivent RespimatIpratropium/Albuterol Sulfate19$9,129
Advair HfaFluticasone Propion/Salmeterol21$7,515
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl67$4,306
Albuterol Sulfate HfaAlbuterol Sulfate85$2,980
Atorvastatin Calcium209$2,164
Ventolin HfaAlbuterol Sulfate32$1,948
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,681
Omeprazole121$1,325
Wixela InhubFluticasone Propion/Salmeterol13$1,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$25$25,96133 claims
Boehringer IngelheimJardiance, Combivent Respimat$16$24,27633 claims
PfizerEliquis$26$16,37112 claims
Astellas Pharma US IncMyrbetriq$85$15,69924 claims
Lilly USA, LLCTrulicity$28$14,36013 claims
MerckJanuvia$26$9,38011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Amherst

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →